Neurology Specific Literature Search   
 
[home][thesaurus]
    

Enter your terms
above and click
the 'Search' button.
Showing articles 0 to 50 of 50

Filter Applied: complications (Click to remove)

Proton Pump Inhibitor and Histamine 2 Receptor Antagonist Use and Vitamin B12 Deficiency
JAMA 310:2435-2442, Lam, J.R.,et al, 2013

Neuropathy in Parkinson Disease
Neurol 77:1947-1950, e132, Rajabally, Y.A. and Martey, J., 2011

Neurologic Manifestations of Long COVID Differ Based on Acute COVID-19 Severity
Ann Neurol 94:146-159, Giraldo,G.S.P.,et al, 2023

Confused About Confusion
NEJM 386:80-87, Spanjaart, A.M.,et al, 2022

Toward Simpler, Safer Treatment of Cryptococcal Meningitis
NEJM 386:1179-1181, Moosa, M.Y.S. & Lessells, R.J., 2022

Use of Marijuana: Effect on Brain Health: A Scientific Statement from the American Heart Association
Stroke 53:e176-e187, Fernando, T.,et al, 2022

Cerebral Microbleeds
Stroke 52:2347-2355, Graff-Radford, J.,et al, 2021

Chemotherapy-Associated Hyperammonemic Encephalopathy
Neurol 94:e874-e877, Briard, J.N.,et al, 2020

Clinicopathologic Conference, Statin-Associated Autoimmune Myopathy
NEJM 381:275-283, Case 22-2019, 2019

Antibody-Mediated Encephalitis
NEJM 378:840-851, Dalmau, J.,et al, 2018

Clinicopathologic Conference, Digitalis Toxicity
NEJM 378:1931-1938, Case 15-2018, 2018

Clinicopathologic Conference, Poststroke Mania and the Frontal Lobe Syndrome
NEJM 379:182-189, Case 21-2018, 2018

Progressive Multifocal Leukoencephalopathy after Treatment with Nivolumab
Emerg Inf Dis 24:1594-1596, Martinot, M.,et al, 2018

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 376:221-234,280, Hauser, S.L.,et al, 2017

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
NEJM 376:209-220,280, Montalban, X.,et al, 2017

A 45-year-old man with Weakness and Myalgia after Orthopedic Surgery
Neurol 88:e185-e189, Vazquez do Campo, R.,et al, 2017

CNS Posttransplant Lymphoproliferative Disorder
Neurol 89:e32-e37, Kesari, N.K.,et al, 2017

Clinicopathologic Conference, Copper Deficiency Myelopathy
NEJM 377:1977-1984, Case 35-2017, 2017

Clinical Outcomes after Neurogenic Stress Induced Cardiomyopathy in Aneurysmal Sub-Arachnoid Hemorrhage: A Prospective Cohort Study
Clin Neurol Neurosurg 128:4-9, Kilbourn, K.J.,et al, 2015

Treatment of Brain Metastases
J Clin Oncol 33:3475-3484, Lin, X. & DeAngelis, L.M., 2015

Sarcoidosis Occurring After Lymphoma: Report of 14 Patients and Review
Medicine 93:e121, London, J.et al, 2014

Sturge-Weber Syndrome
UptoDate , Nov, Bodensteiner, J.B., 2014

Disturbances of Cerebrospinal Fluid, Including Hydrocephalus, Pseudotumor Cerebri, and Low-Pressure Syndromes, Normal Pressure Hydrocephalus
Adams & Victors Principles of Neurology, Chp 30, pg 624, Ropper, A.H.,et al, 2014

Tumor Necrosis Factor-Alpha Inhibitors: An Overview of Adverse Effects
UpToDate January, Stone, J.H., 2013

Long-Term Cognitive Function, Neuroimaging and Quality of Life in Primary CNS Lymphoma
Neurol 81:84-92, Doolittle, N.,et al, 2013

Plasmablastic Lymphoma after Standard-Dose Temozolomide for Newly Diagnosed Glioblastoma
Neurol 81:93-94, Clark, S.,et al, 2013

Autism and Mental Retardation among Offspring born after In Vitro Fertilization
JAMA 310:75-84, Sandin, S.,et al, 2013

Sturge-Weber Syndrome
MedLink Neurology, July, Comi, A.M., 2013

Primary CNS Posttransplant Lymphoproliferative Disease (PTLD): An International Report of 84 Cases in the Modern Era
Am J Transplant 13:1512-1522, Evens, A.M.,et al, 2013

Effects of Fetal Antiepileptic Drug Exposure
Neurol 78:1207-1214, Meador,K.J.,et al, 2012

Diagnosis and Management of Cerebral Venous Thrombosis: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association
Stroke 42:1158-1192, Saposnik,G.,et al, 2011

Folic acid supplementation prevents phenytoin-induced gingival overgrowth in children
Neurol 76:1338-1343, Arya, R.,et al, 2011

Primary Central Nervous System Lymphoma in a Patient Treated with Natalizumab
Ann Neurol 69:1060-1062, Phan-Ba, R.,et al, 2011

Sjogren Syndrome
emedicine.medscape.com,Oct, Miller,A.V., 2011

Primary Central Nervous System Lymphoma
Arch Neurol 67:291-297, Gerstner,E.R. &Batchelor,T.T., 2010

Treatment and Prognosis of Primary Central Nervous System Lymphoma
Up to Date Sept 2010, Hochberg,F.H.,et al, 2010

Hepatitis B Vaccine and the Risk of CNS Inflammatory Demyelination in Childhood
Neurol 72:873-880,870, Mikaeloff,Y.,et al, 2009

Multiple Sclerosis Therapeutics: Unexpected Outcomes Clouding Undisputed Successes
Neurol 72:1008-1015, Wiendl,H. &Hohlfeld,R., 2009

Opportunistic Infections and Other Risks with Newer Multiple Sclerosis Therapies
Ann Neurol 65:367-377, Berger,J.R. &Houff,S., 2009

Cognitive Function at 3 Years of Age After Fetal Exposure to Antiepileptic Drugs
NEJM 360:1597-1605,1667, Meador,K.J.,et al, 2009

Memantine Induces Reversible Neurologic Impairment in Patients with MS
Neurol 72:1630-1633, Villoslada,P.,et al, 2009

Frequency, Characteristics, and Risk Factors for Amiodarone Neurotoxicity
Arch Neurol 66:865-869, Orr,C.F. &Ahlskog,E., 2009

Primary Central Nervous System Lymphoma in a Patient Treated with Natalizumab
Ann Neurol 66:403-406, 261, 262, Schweikert,A.,et al, 2009

Long-Term Outcome in PCNSL Patients Treated with High-Dose Methotrexate and Deferred Radiation
Neurol 70:401-402, Gerstner,E.R.,et al, 2008

Cognition 6 Years After Surgical or Medical Therapy for Coronary Artery Disease
Ann Neurol 63:581-590, Selnes,O.A.,et al, 2008

SLC01B1 Variants and Statin-Induced Myopathy -- A Genomewide Study
NEJM 359:789-799, The SEARCH Collaborative Group, 2008

The Alcohol Withdrawal Syndrome
JNNP 79:854-862, McKeon,A.,et al., 2008

Glatiramer Acetate--Associated, CD30+, Primary, Cutaneous, Anaplastic Large-Cell Lymphoma
Arch Neurol 65:1378-1379, Madray,M.M.,et al, 2008

Risk Factors of Cerebral Vein and Sinus Thrombosis
Front Neurol Neurosci 23:23-54, de Freitas, G.R. & Bogousslavsky, J., 2008



Showing articles 0 to 50 of 50